Provided by Tiger Fintech (Singapore) Pte. Ltd.

AIM ImmunoTech

0.1348
+0.00181.35%
Volume:173.42K
Turnover:23.25K
Market Cap:9.27M
PE:-0.29
High:0.1414
Open:0.1367
Low:0.1300
Close:0.1330
Loading ...

Coherent Announces Launch of AIM Family of Industrial, Rack-Based Multi-Kilowatt Single Mode Fiber Lasers

GlobeNewswire
·
2 hours ago

AIM Vaccine's Rabbies Vaccine Gets NMPA Nod for Clinical Trials; Shares Slide 17%

MT Newswires Live
·
11 hours ago

AIM Vaccine Secures Approval for Advanced Rabies Vaccine, Bolstering Global Market Position

TIPRANKS
·
Yesterday

Hargreave Hale AIM VCT plc Cancels 237,784 Shares

TIPRANKS
·
06 Mar

Wellnex Life Secures $2.2 Million, Eyes Dual Listing on AIM

TIPRANKS
·
05 Mar

CEO Makes Bold Move with Major AIM ImmunoTech Stock Purchase

TIPRANKS
·
05 Mar

Private companies are AIM Vaccine Co., Ltd.'s (HKG:6660) biggest owners and were hit after market cap dropped HK$400m

Simply Wall St.
·
04 Mar

Viant Technology Announces Acquisition of Lockr

Business Wire
·
04 Mar

Amati AIM VCT Announces Total Voting Rights Update

TIPRANKS
·
03 Mar

Creightons PLC to Transition Shares from Main Market to AIM

TIPRANKS
·
03 Mar

RA International to Delist from AIM Following Shareholder Approval

TIPRANKS
·
01 Mar

Amati AIM VCT Appoints Maven as New Investment Manager and Expands Board

TIPRANKS
·
28 Feb

Hargreave Hale AIM VCT PLC Announces Total Voting Rights

TIPRANKS
·
28 Feb

Aim Announces Paul Goepfert, Md, as the Principal Investigator for the Planned Clinical Study of Ampligen and Flumist as a Vaccine for Avian Influenza

THOMSON REUTERS
·
28 Feb

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

GlobeNewswire
·
28 Feb

AIM Vaccine Eyes HK$74.7 Million from Share Placement; Shares Slide 12%

MT Newswires Live
·
28 Feb